Skip to main content
SpringerLink
Log in

Future and emerging therapies

  • Chapter
  • First Online:
Handbook of Incretin-based Therapies in Type 2 Diabetes

Abstract

This chapter is focused on investigational drugs, new methods of administration, and potential new indications of glucagon-like peptide-1 (GLP-1)-based therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY21189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26:287-296.

    Google Scholar 

  2. Barrington P, Chien JY, Tibaldi F, Showalter HD, Scheneck K, Ellis B. LY21189265, a long-acting glucagon-like peptide-1 analogue showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab. 2011;13:434-438.

    Google Scholar 

  3. Wysham C, Blevins T, Arakaki R, et al. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care. 2014;37:2159-2167.

    Google Scholar 

  4. Lilly Diabetes. Lilly announces positive results of Phase III trials of dulaglutide in type 2 diabetes. https://investor.lilly.com/releasedetall. Accessed October 5, 2015.

  5. Umpierrez G,Povedano ST, Manghi FP, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37:2168-2176.

    Google Scholar 

  6. Jendle J, Rosenstock J, Blonde L, et al. Better glycemic control and less weight gain with once-weekly dulaglutide vs once-daily insulin glargine, both combined with pre-meal insulin lispro, in type 2 diabetes patients (AWARD-4). Diabetes. 2014;(suppl1):A246-A247.

    Google Scholar 

  7. Nauck M, Wistock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37:2149-2158.

    Google Scholar 

  8. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non inferiority trial. Lancet. 2014;384:1349-1357.

    Google Scholar 

  9. Skrivanek Z, Gaydos BL; Chien JY, et al. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5). Diabetes Obes Metab. 2014;16:748-756.

    Google Scholar 

  10. Kapitza C, Lynge J, Düring M, Jensen C. Safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD) of single escalating doses of semaglutide, a unique once weekly GLP-1 analogue, in healthy male subjects. Diabetologia. 2012;55(suppl1):S341. Abstract 826.

    Google Scholar 

  11. Nauck MA, Petrie, JR, Sesti G, et al. The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes. Diabetologia. 2012;55(suppl 1):S7.

    Google Scholar 

  12. Marbury TC, Flint A, Segel S, Lindegaard M, Lasseter K. Pharmacokinetics and tolerability of a single dose of semaglutide, a once-weekly human GLP-1 analog, in subjects with and without renal impairment. Diabetes. 2014;63(suppl 1):A260

    Google Scholar 

  13. Henry RR, Logan D, Alessi TM Baron MA. A randomized, open-label, multicentre, 4 week study to evaluate the tolerability and pharmacokinetics of ITCA 650, in patients with type 2 diabetes. Clin Ther. 2013;35:634-635.

    Google Scholar 

  14. Henry RR, Rosenstock J, Logan D, Alessi TM, Lusey K, Baron MA. Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes. Diabetes Care. 2013;36:2559-2565.

    Google Scholar 

  15. Henry RR, Rosenstock J, Logan D, Alessi TM, Lusey K, Baron MA. Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J Diab Comp. 2014;28:393-398.

    Google Scholar 

  16. Alessi T, Henry R, Rosenstock J, Luskey K. Improved patient satisfaction with ITCA 650 vs exenatide injections in subjects with metformin-treated type 2 diabetes. Diabetologia. 2011;54(suppl1):S.

    Google Scholar 

  17. Intarcia Therapeutics. Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results. intarcia.com/media/press-releases/2015-sep-16-easd.html. Accessed October 5, 2015.

    Google Scholar 

  18. Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects. https://www.clinicaltrials.gov/ct2/show/NCT01272973. Accessed October 5, 2015.

  19. Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab. 2013;15:485-502.

    Google Scholar 

  20. Gough SCL, Buse JB, Woo VC, et al. IDegLira, a novel fixed-ration combination of insulin degludec and liraglutide, is efficacious and safe in subjects with type 2 diabetes: a large, randomized phase 3 trial. Diabetologia. 2013;56(suppl1):S96.

    Google Scholar 

  21. Gough SCL, Buse JB, Woo VC, et al. One-year efficacy and safety of IDegLira in patients with type 2 diabetes. Diabetes. 2014; 63(suppl1): A17.

    Google Scholar 

  22. Buse JB, Vilsboll T, Thurman J, et al. Contribution of liraglutide in the fixed-ration combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014;37:2926-2933.

    Google Scholar 

  23. Rosenstock J, Diamant M, Silvestre L, et al. Benfits of a fixed-ratio of once-daily insulin glargine/lixisenatide (LixiLan) vs glargine in type 2 diabetes (T2DM) inadequately controlled on metformin. Diabetes. 2014; 63(suppl1): A87.

    Google Scholar 

  24. A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With T2DM. http://clinicaltrials.gov/ct2/show/NCT02058160. Accessed October 5, 2015.

  25. A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus T2DM. http://clinicaltrials.gov/ct2/show/NCT02058147. Accessed October 5, 2015.

  26. Patel S, DeFronzo A, Lewin D, et al. Fixed dose combinations of empagliflozin/linagliptin for 52 weeks as add-on to metformin in subjects with type 2 diabetes. Presented at: the 50th Meeting of European Association for Study of Diabetes (EASD); Sept 15-19, 2014; Vienna, Austria. www.easdvirtualmeeting.org/resources/19597. Accessed October 5, 2015.

  27. A Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Once Daily Oral Administration of BI 10773 25 mg/Linagliptin 5 mg and BI 10773 10 mg/Linagliptin 5 mg Fixed Dose Combination Tablets Compared With the Individual Components (BI 10773 25 mg, BI 10773 10 mg, and Linagliptin 5 mg) for 52 Weeks in Treatment-naïve and Metformin Treated Patients With Type 2 Diabetes Mellitus With Insufficient Glycemic Control. http://clinicaltrials.gov/show/NCT01422876. Accessed October 5, 2015.

  28. A Single-dose, Open-label, Randomized, 3 Period, 3 Treatment Crossover Study to Evaluate the Pharmacokinetics of Saxagliptin 5 mg and Dapagliflozin 10 mg When Co-administered to Fasted Healthy Subjects. http://clinicaltrials.gov/show/NCT01662999. Accessed October 5, 2015.

  29. A Double-Blind Placebo-Controlled Study of Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults With Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder. http://clinicaltrials.gov/ct2/show/NCT00845507. Accessed October 5, 2015.

  30. Lorenz M, Evers A, Wagner M. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg Med Chem Lett. 2013;23:4011-4018.

    Google Scholar 

  31. Panchapakesan U, Mather A, Pollock C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clin Sci (London). 2013;124:17-26.

    Google Scholar 

  32. Astrup A, Carraro R, Harper A, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog liraglutide. Int J Obesity. 2012;36:834-854.

    Google Scholar 

  33. Sarkar G, Alattar M, Brown RJ, et al. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care. 2014 37:666-670.

    Google Scholar 

  34. Kuhadiya ND, Malik R, Bellini NJ, et al. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract. 2013;19:963-967.

    Google Scholar 

  35. Varanasi A1, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol. 2011;165:77-84.

    Google Scholar 

  36. Ghazi T, Rink L, Sherr JL, Herold KC. Acute metabolic effects of exenatide in patients with Type 1 diabetes with and without residual insulin to oral and IVglucose challenges. Diabetes Care. 2014;37:210-216.

    Google Scholar 

  37. Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus. https://www.clinicaltrials.gov/ct2/show/NCT02284009. Accessed October 5, 2015.

  38. Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide 1 can directly protect the heart againts ischemia/reperfusion injury. Diabetes. 2005;54:146-151.

    Google Scholar 

  39. Nikolaidis LA, Mankad S, Sokos GG, et al .Effects of glucagon-like peptide-1 in patients with acute myocardial infartion and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962-965.

    Google Scholar 

  40. Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) (ELIXA). http://clinicaltrials.gov/ct2/show/NCT01147250. Accessed October 5, 2015.

  41. Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation (LEADER®). http://clinicaltrials.gov/ct2/show/NCT01179048. Accessed October 5, 2015.

  42. Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus. http://clinicaltrials.gov/ct2/show/NCT01144338. Accessed October 5, 2015.

  43. Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND). http://clinicaltrials.gov/ct2/show/NCT01394952. Accessed October 5, 2015.

  44. A Study to Evaluate Cardiovascular Outcomes in Patients with Type 2 Diabetes Treated With ITCA 650. www.clinicaltrials.gov/ct2/show/NCT01455896. Accessed October 5, 2015.

  45. Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus. http://clinicaltrials.gov/ct2/show/NCT01720446. Accessed October 5, 2015.

  46. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-1335.

    Google Scholar 

  47. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326.

    Google Scholar 

  48. Sitagliptin Cardiovascular Outcome Study (MK-0431-082) (TECOS). https://clinicaltrials.gov/ct2/show/NCT00790205. Accessed October 5, 2015.

  49. CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes. https://clinicaltrials.gov/ct2/show/NCT01243424. Accessed October 5, 2015.

  50. Wu S, Hopper I, Skriba M, Krum H. Dipeptidyl-peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014;32:147-158.

    Google Scholar 

  51. Kanasaki K, Shi S, Kanasaki M, et al. Linagliptin-mediated inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mica by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014;63:2120-2131.

    Google Scholar 

  52. Panchapakesan U, Pollock CA. DPP-4 inhibitors-renoprotection in diabetic nephropathy? Diabetes. 2014;63:1829-1830.

    Google Scholar 

  53. Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA). www.clinicaltrials.gov/ct2/show/NCT01272973. Accessed October 5, 2015.

Download references

Author information

Authors and Affiliations

  1. University of Barcelona, Barcelona, Spain

    Eduard Montanya

Authors
  1. Eduard Montanya
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oxford Ctre for Diabe, Endocrngy & Metab, Oxford University, Oxford, Oxfordshire, United Kingdom

    Stephen Gough

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Montanya, E. (2016). Future and emerging therapies. In: Gough, S. (eds) Handbook of Incretin-based Therapies in Type 2 Diabetes. Adis, Cham. https://doi.org/10.1007/978-3-319-08982-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-08982-9_6

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-08981-2

  • Online ISBN: 978-3-319-08982-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation